Pharmamarketeer
onderzoek

Valneva COVID-19 vaccine shown to be more effective than AstraZeneca candidate

19 oktober 2021
InPharm.com

French biotech company, Valneva, has announced positive results from the Phase III trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

The Phase III, Cov-Compare trial recruited a total of 4,012 participants, aged 18 years and older, across 26 trial sites in the UK. The trial successfully met both co-primary endpoints: VLA2001 had superior antibody titer levels compared to the active comparator vaccine, AstraZeneca’s AZD1222, and it had a neutralising antibody seroconversion rate above 95%.

 

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)